TECH earnings

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growthGrowth vectors performed well, with mid‑single‑digit growth in Proteomic Analy

MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time:8:00 a.m. CDTDate:May 6, 2026Dial-in:1-800-343-4136 or 1-203-518-9843 (for international callers)Conference ID:TECHQ3Webcast:https://investors.bio-techne.com/ir-calendarA recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 111

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive

MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 4, 2026 Dial-in:  1-800-579-2543 or 1-785-424-1789 (for international callers) Conference ID: TECHQ2 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and r

MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million.GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025. Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars. Ongoing productivity and cost containment initiatives led

MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time:                    8:00 a.m. CST Date:                      November 5, 2025 Dial-in:    1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID:      TECHQ1 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-

MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million. Full year organic revenue increased 5% (5% reported) to $1.2 billion.GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago. Delivered adjusted EPS of $0.53 compared to $0.49 one year ago. Full year GAAP EPS was $0.46 versus $1.05 one year ago. Full year adjusted EPS was $1.92 versus $1.77 one year ago.Strong performance in our proteomic analytic and cell therapy growth pillars drove 4% organic growth (6% rep

MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referen

MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

MINNEAPOLIS, April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time:            8:00 a.m. CDT Date:                      May 7, 2025 Dial-in:    1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID:      13753150 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-3

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago.Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy workflow solutions, led to 8% organic growth in our Protein Sciences Segment (7% reported).Strong commercial execution in Diagnostics & Spatial Biology led to 12% organic growth (12% report

MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 5, 2025 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID:   13751305 Webcast:         https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers)

MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offeri

MINNEAPOLIS, Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 30, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13749405 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and refere

MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion.GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was $1.05 versus $1.76 one year ago. Full year adjusted EPS was $1.77 versus $1.99 one year ago.Strong commercial execution in Diagnostics & Genomics led to 9% organic segment growth (15% reported) in the fo

MINNEAPOLIS, July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time:      8:00 a.m. CDT Date:      August 7, 2024 Dial-in:      1-800-343-4136 or 1-203-518-9843 (for international callers) Conference ID:      BioTechne Webcast:      https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested

MINNEAPOLIS, May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million.GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago.Strong commercial execution in Diagnostics & Genomics led to 10% organic segment growth (16% reported).Continued uptake of our cell and gene therapy workflow solutions, including record sales for our GMP reagent portfolio.Cash flow generated from operations increased to $223.5 million, a 31% increas

MINNEAPOLIS, April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13745802 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Confere

MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights Second quarter organic revenue declined by 2% (0% reported) to $272.6 million. Organic revenue remained flat (2% reported) in the first half of fiscal 2024 at $549.5 million.GAAP earnings per share (EPS) was $0.17 versus $0.31 one year ago. Adjusted EPS of $0.40 compared to $0.47 one year ago.The impact of the BioPharma macroeconomic conditions that the industry has experienced throughout the past calendar year increased in our fiscal second quarter. The company has been able to partially offset th

MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024, at 8:00 a.m. CST to review second quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 1, 2024 Dial-in:  1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13743935 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referenci

MINNEAPOLIS, Oct. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023, at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 31, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13741775 Webcast: https://investors.bio-technecom/ir-calendar   A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing

MINNEAPOLIS, Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2023. Fourth Quarter FY2023 Highlights Fourth quarter organic revenue increased by 5% (5% reported) to $301.3 million. Full year organic revenue increased 5% (3% reported) to $1.1 billion.GAAP earnings per share1) (EPS) was $0.47 versus $0.38 one year ago. Delivered adjusted EPS1) of $0.55 compared to $0.51 one year ago. Full year GAAP EPS was $1.76 versus $1.66 one year ago. Full year adjusted EPS was $1.99 versus $1.97 one year ago.Strong commercial execution in Diagnostics and Genomics led to 10% organic segment growth (10% reported) in

MINNEAPOLIS, July 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023, at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results. Access to the discussion may be obtained as follows: Time:                    8:00 a.m. CDT Date:                      August 8, 2023 Dial-in:    1-877-300-8521 or 1-412-317-6026 (for international callers) Conference ID:      10180893 Webcast:                  https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2

MINNEAPOLIS, May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2023. Third Quarter FY2023 Highlights Third quarter organic revenue increased by 3% (1% reported) to $294.1 million and 4% (2% reported) in the first nine months of fiscal 2023 to $835.4 million.GAAP earnings per share1) (EPS) was $0.43 versus $0.37 one year ago. Delivered adjusted EPS1) of $0.53, consistent with prior year adjusted EPS.Successful execution within our cell and gene therapy growth platform with another record quarter in GMP protein sales and completion of a 20% ownership stake in Wilson Wolf.Increased ExoDx Prostate test adop

MINNEAPOLIS, April 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023, at 8:00 a.m. CDT to review third quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 3, 2023 Dial-in: 1-877-300-8521 or 1-412-317-6026 (for international callers) Conference ID: 10177426 Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1607083&tp_key=a481261dfe A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and

MINNEAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2022. Second Quarter FY2023 Highlights Second quarter organic revenue increased by 4% (1% reported) to $271.6 million and 5% (3% reported) in the first half of fiscal 2023 to $541.2 million.GAAP earnings per share1) (EPS) was $0.31 versus $0.49 one year ago. Delivered adjusted EPS1) of $0.47, consistent with the prior year, with foreign currency exchange negatively impacting EPS by $0.02 per share when compared to the prior year.Growth in the ExoDx Prostate test continued with its fourth consecutive record quarter, as tests performed gr

MINNEAPOLIS, Jan. 17, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023, at 8:00 a.m. CST to review second quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 2, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13735661 Webcast: https://viavidwebcastscom/startherejsp?ei=1594125&tp_key=12f30d96f5 A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers

MINNEAPOLIS, Nov. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2022. First Quarter FY2023 Highlights First quarter organic revenue increased by 7% (5% reported) to $269.7 million.GAAP EPS was $2.21 versus $1.69 one year ago. Current year adjusted earnings per share (EPS) of $1.78 was negatively impacted by $0.12 of unfavorable foreign currency exchange when compared to prior year adjusted earnings per share of $1.83.Diagnostics and Genomics achieved 17% organic growth with strong execution across its entire portfolio.Delivered operating cash flow of $56.1 million, an increase of 16% when compared t

MINNEAPOLIS, Oct. 10, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022, at 8:00 a.m. CDT to review first quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: November 1, 2022 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13733551 Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1575794&tp_key=2a97c8f47a A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international calle

MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2022. Fourth Quarter FY2022 Highlights Fourth quarter organic revenue increased by 14% (11% reported) to $288.2 million. Full year organic growth of 17% (19% reported) to $1.1 billion.GAAP EPS was $1.51 versus $0.37 one year ago. Delivered adjusted earnings per share (EPS) of $2.05, an increase of 9% from the prior year. Full year GAAP EPS was $6.63 vs $3.47 a year ago. Achieved record full year adjusted EPS of $7.89, an increase of 17% from the prior year.Sustained operational excellence across the organization, including Protein Sciences

MINNEAPOLIS, July 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Thursday, August 4, 2022, at 8:00 a.m. CDT to review fourth quarter 2022 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m CDT Date: August 4, 2022 Dial-in: 1-800-926-5187 or 1-312-281-2972 (for international callers) Conference ID: 22019664 Webcast: https://viavidwebcastscom/startherejsp?ei=1559480&tp_key=e7f9b5f18b A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and

MINNEAPOLIS, May 4, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2022. Third Quarter FY2022 Highlights Third quarter organic revenue increased by 17% (19% reported) to $290.4 million and 18% (22% reported) in the first nine months of fiscal 2022 to $817.4 million. GAAP EPS was $1.48 versus $1.12 one year ago. Delivered record adjusted earnings per share (EPS) of $2.14 versus $1.80 one year ago. Excellent commercial execution in both operating segments with Protein Sciences delivering organic growth of  16% (15% reported) and Diagnostics and Genomics achieving 19% (34% reported) organic growth. Announced e

MINNEAPOLIS, April 13, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 4, 2022 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13728915 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Confere

MINNEAPOLIS, Feb. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2021. Second Quarter FY2022 Snapshot Second quarter organic revenue increased by 17% (20% reported) to $269.3 million and 19% (23% reported) in the first half of fiscal 2022 to $527.0 million. Sustained operational excellence in Protein Sciences which achieved 19% organic growth (19% reported) in the second fiscal quarter, including a 27% increase in ProteinSimple branded analytical solutions and over 180% growth in GMP Proteins. Adjusted operating income increased 18% (22% reported) when compared to the prior year to $102.8 million, re

MINNEAPOLIS, Jan. 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, February 1, 2022, at 8:00 a.m. CST to review second quarter fiscal 2022 financial results. Access to the discussion may be obtained as follows: Time:  8:00 a.m. CST Date:  February 1, 2022 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13726340 Webcast:  https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referen

MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021. First Quarter FY2022 Snapshot First quarter organic revenue increased by 21% (26% reported) to $257.7 million.   GAAP EPS was $1.69 versus $0.83 one year ago. Delivered adjusted earnings per share (EPS) of $1.83 versus $1.43 a year ago.   Protein Sciences achieved 26% organic growth, its third consecutive quarter of organic growth above 20%.   Adjusted operating income increased 25% (29% reported) when compared to the prior year.   Excellent commercial execution in all major geographic regions, with North America and Europe organi

MINNEAPOLIS, Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a.m. CDT to review first quarter 2022 financial results. Access to the discussion may be obtained as follows: Time:                    8:00 a.m. CDT Date:                     November 2, 2021 Dial-in:   1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID:      13724007 Webcast:                https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1

MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021. Fourth Quarter FY2021 Snapshot Fourth quarter organic revenue increased by 39% (47% reported) to $259.0 million. Full year organic growth of 22% (26% reported) to $931.0 million. GAAP EPS was $0.37 versus $1.48 one year ago. Delivered adjusted earnings per share (EPS) of $1.87 versus $1.00 one year ago. Full year GAAP EPS was $3.47 vs $5.82 one year ago. Full year adjusted EPS was $6.75 vs $4.55 in the prior year. Adjusted Operating Margin increased to 38.5% in the fourth quarter of fiscal 2021 compared to 31.1% in the fourth quarter